Parp Inhibitors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Parp inhibitors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Parp Inhibitors Today - Breaking & Trending Today

Olaparib combo improves PFS in metastatic prostate cancer

Frontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer. ....

United Kingdom , British Columbia , United States , Maha Hussain , Kimn Chi , Roberth Lurie Comprehensive Cancer Center , Prostate Cancer Working Group , University Of British Columbia , Comprehensive Cancer Center , Both Dr Hussain , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Of The Prostate , Breast Cancer , Alignant Breast Neoplasm , Breast Carcinoma , Alignant Neoplasia , Alignant Neoplasm , Ovarian Cancer Malignant Neoplasm , Ovary Cancer , Genomics Genomic Medicine , Parp Inhibitors , Parp Inhibition , Oly Adp Ribose Polymerase Inhibitor ,

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies, which he notes are vital for moving the paradigm forward and ultimately improving patient outcomes. ....

Myrtle Beach , South Carolina , United States , Carolina Urologic Research Center , Neal Shore , Genesiscare United States , 177lu Psma 617 , Prostate Cancer , Radioligand Therapy , Parp Inhibitors ,

Recent Developments in Ovarian and Endometrial Cancers Stir Excitement Among Clinicians

Despite advanced ovarian and endometrial cancer still being accompanied by a poor prognosis and remaining largely difficult-to-treat diseases, optimism among clinicians has steadily ramped up in recent years with the development of multiple new promising agents and treatment regimens. ....

United States , Ursulaa Matulonis , Matthewa Powell , Bhavana Pothuri , International Federation Of Gynecology , American Society Of Clinical Oncology , Onclive Peer Exchange , Onclive Peer , Clinical Oncology , International Federation , Checkpoint Inhibitors , Endometrial Cancer , New England Journal , Ovarian Cancer , Gynecologic Oncology , Parp Inhibitors , Immune Checkpoint Inhibitors ,

Merck KGaA Puts Up €160M for Drug to Rival DNA Damage Cancer Meds From AstraZeneca, Gilead

A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate. ....

Merck Kgaa Hengrui , Daiichi Sankyo , Merck Kga , Jiangsu Hengrui Pharmaceuticals , Gilead Sciences , Merck Kgaa , Jiangsu Hengrui , China Based Hengrui , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery ,

The Role of Combination Therapy in mCRPC

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer. ....

Prostate Cancer Treatment Landscape , Combination Therapy , Prostate Cancer , Prostate Cancer Treatments , Parp Inhibitors , Metastatic Castrate Resistant Prostate Cancer , Radium 223 ,